Summary: For decades, antidepressant treatment focused mainly on medications that altered monoamines such as serotonin and norepinephrine—drugs that often take weeks to relieve symptoms, and that fail for many patients. A major shift in research has reframed our understanding by revealing the rapid antidepressant effects of ketamine.
Unlike conventional antidepressants, ketamine acts on the brain’s glutamate system. By stimulating the rapid regrowth of neural connections (synaptogenesis) damaged by chronic stress, ketamine can reduce depressive symptoms and suicidal thoughts within hours rather than weeks, offering a critical option for people with treatment-resistant depression or acute suicidal crisis.
Key Facts
- The glutamate perspective: Depression involves more than a simple serotonin imbalance. Research shows structural changes in the brain—linked to glutamate signaling and synaptic loss—play a central role.
- Fast synaptogenesis: Ketamine triggers a surge of glutamate that promotes the formation of new synapses, helping to restore neural networks that support mood, motivation, and cognition.
- Hours, not weeks: While selective serotonin reuptake inhibitors (SSRIs) can take several weeks to work, ketamine often produces measurable improvement in 1 to 4 hours.
- Treatment-resistant cases: Clinical studies indicate ketamine can help many patients who did not respond to at least two prior antidepressant treatments.
- From anesthetic to antidepressant: Ketamine began as an anesthetic. Research at Yale and elsewhere led to the development and regulatory approval of esketamine (marketed as Spravato), a nasal formulation derived from the ketamine molecule.
Source: Yale
Rising depression rates and the limits of slow-acting medications have intensified the search for faster, more effective therapies—especially for people whose symptoms do not respond to available treatments.
At Yale School of Medicine, decades of research in neuroscience and psychiatry converged on an unexpected candidate: ketamine. Studies there helped shift scientific thinking about depression toward neuroplasticity and rapid-acting interventions.
In 2000, John Krystal, MD, reported that ketamine could rapidly relieve symptoms of major depression, often within hours after a single intravenous dose. This was the first major advance in pharmacological treatment for depression in many years, and it opened a new avenue of research focused on glutamate and synaptic repair rather than exclusively on monoamine neurotransmitters.
Origins of ketamine
Ketamine was first synthesized in 1962 as a safer derivative of phencyclidine (PCP) and approved for medical use in 1970 as a short-acting anesthetic. It was widely adopted in surgical and emergency settings because of its rapid and reliable anesthetic properties. Later, ketamine also became known as an illicit recreational drug, but scientific interest persisted in its unique effects on the brain—particularly its modulation of glutamate, a neurotransmitter essential for learning, memory, and neural connectivity.
A new scientific direction in depression treatment
Krystal’s early work, followed by additional studies at Yale and elsewhere, showed that ketamine produces rapid antidepressant effects distinct from the slower mechanisms of SSRIs. Neuroscientist Ronald S. Duman and colleagues elucidated how ketamine-induced glutamate release promotes the formation of new synapses, effectively “re-wiring” critical circuits involved in mood and cognition. These newly formed connections allow patients to experience improvements in mood and cognitive function much faster than with traditional antidepressants.
Because the drug acts on neuroplastic processes, relatively low doses can produce meaningful benefits. Many clinical protocols use an initial series of treatments—a loading phase—followed by maintenance sessions to preserve the gains and support ongoing synaptic strength.
Scientific and clinical reception
Initial skepticism gave way to broader acceptance as repeated studies confirmed ketamine’s rapid, robust antidepressant effects. By the 2010s, clinicians began to incorporate ketamine-based treatments for patients with severe, treatment-resistant depression. Further development produced esketamine, a refined compound designed to retain therapeutic effects while improving tolerability and enabling a practical delivery method for outpatient settings.
Clinical trials of esketamine showed substantial benefits for many people who had not responded to other treatments. In some studies, a significant proportion of participants experienced rapid symptom reduction within 24 hours, and regulatory agencies later approved esketamine nasal spray for treatment-resistant depression and for adults at risk of suicide.
Research also suggests the benefits of ketamine extend beyond major depression: investigators are exploring its potential in PTSD, depression associated with neurologic disease, bipolar disorder, and chronic stress-related conditions. These efforts reflect a broader shift toward therapies that harness neuroplasticity to produce faster, more durable clinical improvements.
Key Questions Answered:
A: Illicit recreational use of ketamine is distinct from its medical application. In clinical settings, ketamine is given in precise, low doses under medical supervision. At therapeutic doses it promotes neuroplasticity, helping damaged or dormant neurons reconnect and improving mood and cognitive function.
A: The duration varies by individual and protocol. A single infusion or dose can provide relief lasting from several days up to two weeks. Typical clinical practice includes a series of initial treatments followed by maintenance doses to sustain the newly formed neural connections and ongoing symptom control.
A: Ketamine can temporarily raise blood pressure and heart rate, so it is administered under medical supervision with monitoring. It is most commonly used for patients with treatment-resistant depression or acute suicidal ideation who have not benefited from conventional therapies.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by staff.
About this ketamine and depression research news
Author: Colleen Moriarty
Source: Yale
Contact: Colleen Moriarty – Yale
Image: The image is credited to Neuroscience News